- 期刊
Clinical Outcome of Primary Gastric Lymphoma Treated with Chemotherapy Alone or Surgery Followed by Chemotherapy
並列摘要
Background: The role of surgical resection in the treatment of primary gastric lymphoma (PGL) remains unclear. This retrospective study evaluated the clinical outcome of PGL treated with chemotherapy alone or surgery followed by chemotherapy. Methods: During 1986-2003, 59 patients with PGL (other than mucosa-associated lymphoid tissue type lymphoma) were identified from hospital files. The medical records, pathologic sections, radiographic images and treatment modalities of these patients were reviewed. Patients were categorized into localized (stage ⅠE and ⅡE-1) and advanced (stage ⅡE-2 or beyond) stage groups. Survival was estimated by the Kaplan-Meier method. Results: The study included 55 patients who received treatment at the same institute. Among them, 32 had localized PGL (15 stage ⅠE, 17 stage ⅡE-1) and 23 had advanced disease. The median survival of the localized stage group was not reached during a mean follow-up of 168.1±16.7 months (95% confidence interval [CⅠ], 135.4-200.8 months), while that of the advanced stage group was 33.0±6.8 months (95% CⅠ, 19.7-46.5; p＜0.001, log-rank test). Among patients with localized PGL, the 5-year overall survival rate of those receiving chemotherapy alone (n=19) or combination therapy (surgery followed by chemotherapy, n=13) was 73.4% and 87.5%, respectively (p=0.229). The 5-year disease-free survival was 68.4% and 84.6%, respectively (p=0.540). However, post-chemotherapy life-threatening hemorrhage occurred in five of the 32 patients (15.6%) in the localized stage group: four in the chemotherapy-alone group, and one in the combination therapy group, all of whom had failed to achieve complete response. Conclusion: The clinical outcome of localized PGL treated by chemotherapy alone is similar to that treated by surgery followed by chemotherapy in terms of tumor response, disease-free survival and overall survival, suggesting that surgery be reserved for those with residual tumors after chemotherapy.
延伸閱讀
- Zhang, C., Li, A., Li, H., Peng, K., Wei, Q., Lin, M., Liu, Z., Yin, L., & Li, J. (2015). PPP1R12A Copy Number Is Associated with Clinical Outcomes of Stage III CRC Receiving Oxaliplatin-Based Chemotherapy. Mediators of Inflammation, 2015(), 928-934-188. https://doi.org/10.1155/2015/417184
- Hung, W. H. (2016). Chemotherapy Treatment Patterns and Survival Outcomes among Gastric Cancer Patients [master's thesis, Kaohsiung Medical University]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0011-1307201616554900
- 鄭惠鑫、陳雅惠、王琦、廖梅珍（2008）。Distress Symptoms and Health Education Demands during among Gynecologic Oncology Patients Undergoing Chemotherapy。腫瘤護理雜誌，8(2)，45-57。https://doi.org/10.6880/TJON.200812_8(2).05
- Hyodo, I., Fukuda, K., & Endo, S. (2007). The Coming New Era for Progress of Chemotherapy for Unresectable and Recurrent Gastric Cancer. 中華民國癌症醫學會雜誌, 23(S), 39-43. https://doi.org/10.6588/JCOS.2007.23.S.11
- Cheng, C. F., Chang, I. Y., & Lin, C. P. (2006). Chemotherapy and Radiotherapy in Gastric Cancer. 北市醫學雜誌, 3(6), 581-589. https://doi.org/10.6200/TCMJ.2006.3.6.06